MedWatch

Travel restrictions bite Bavarian as rabies vaccine sales plunge

At the end of Q1, Bavarian Nordic presented shrinking sales of vaccines Rabipur/Rabavert against rabies and Encepur against TBE.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish biotechnology company Bavarian Nordic's vaccine against rabies has been tripped up by the covid-19 pandemic and resulting travel restrictions, the firm's Vice President Investor Relations & Communications Rolf Sass Sørensen tells Ritzau Finans following the publication of the firm's Q1 report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs